Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis

Cancer patients with autoimmune disease (AID) are usually excluded from clinical trials involving immune checkpoint inhibitors (ICIs). The available electronic databases were systematically searched from inception until July 3, 2022. We recorded the incidence of immune-related adverse events (irAEs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Qi, Huo, Geng-wei, Zhu, Fu-yi, Yue, Ping, Yuan, Dong-qi, Chen, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Immunotherapeutics – Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762847/
https://www.ncbi.nlm.nih.gov/pubmed/36471629
http://dx.doi.org/10.1080/21645515.2022.2145102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762847/
https://www.ncbi.nlm.nih.gov/pubmed/36471629
http://dx.doi.org/10.1080/21645515.2022.2145102

Ejemplares similares